<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04107727</url>
  </required_header>
  <id_info>
    <org_study_id>QUIWI</org_study_id>
    <nct_id>NCT04107727</nct_id>
  </id_info>
  <brief_title>Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>A 2:1 Randomized Phase II Trial to Compare the Efficacy and Safety of Standard Chemotherapy Plus Quizartinib Versus Standard Chemotherapy Plus Placebo in Adult Patients With Newly Diagnosed FLT3 Wild-type AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dynamic Science S.L.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized phase II trial to compare the efficacy and safety of standard chemotherapy plus
      quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed
      FLT3 wild-type Acute Myeloid Leukemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, prospective, randomized, placebo-controlled, double-blinded phase II trial to
      assess the efficacy and safety of an oral quizartinib vs. placebo containing front-line
      chemotherapy-based schedule in FMS-like tyrosine kinase 3 internal tandem duplications
      (FLT3-ITD) wild-type Acute Myeloid Leukemia patients.

      The trial will be conducted in two phases:

      An open-label safety run-in phase: Cytarabine 200 mg/m2 (days 1-7), Idarubicin 12 mg/m2 (days
      1-3) Quizartinib 60 mg/d x 14 days (30mg with strong Cytochrome P450 Family 3 Subfamily A
      (CYP3A) inhibitor) in a total of 9 patients, being observed during 1 cycle of induction to
      define the final dose for the randomized phase.

      A randomized double-blinded phase 2:1 quizartinib (at the established dose) vs. placebo.

      Experimental Arm: Cytarabine 200 mg/m2 (days 1-7), Idarubicin 12 mg/m2 (days 1-3) Quizartinib
      60 mg/d x 14 days (30mg with strong CYP3A inhibitor) Standard Arm: Cytarabine 200 mg/m2 (days
      1-7), Idarubicin 12 mg/m2 (days 1-3) Placebo 60 mg/d x 14 days (30mg with strong CYP3A
      inhibitor)

      272 patients will be included in this phase.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2019</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Safety run-in phase: multicenter, prospective, open-label.
Phase II: multicenter, prospective, randomized, placebo-controlled, double-blinded</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Subjects will be randomized into 1 of the 2 treatment groups (quizartinib or placebo) in a 2:1 ratio. The randomization will be stratified by age (&lt;60 vs. ≥60 years old) at the time of diagnosis of AML. Neither the subjects nor any of the Investigators, Sponsor, or contract research organizations (CROs) will be aware of the treatments received. An independent biostatistician, not otherwise part of the study team, will generate the randomization schedule.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival rate</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Time from randomization to the date of the occurrence of any of the following events: CR/CRi after 1 or 2 induction cycles, death in CR/CRi or relapse, whichever occurs the first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum dose tolerated (MDT) and recommended phase 2 dose (Safety run-in phase)</measure>
    <time_frame>At the end of Cycle 1 of Induction and up to 59 days (Safety run-in phase)</time_frame>
    <description>To determine the maximum dose tolerated (MDT) and the recommended phase 2 dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Complete Remission (CR/CRi) with minimal residual disease (MRD) negativity</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>The proportion of subjects with complete response or complete remission with incomplete blood count recovery with Minimal residual disease negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Adverse events between experimental quizartinib containing schedule and standard arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>To compare the time from the first documentation of remission to the documentation of disease recurrence or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>The number of days from randomization until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of Relapse</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>To compare the time from the date of first Complete Response until date of hematological or extramedullary relapse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">281</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Quizartinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction: Cytarabine continuous IV infusion 200 mg/m2 (days 1-7), Idarubicin IV infusion 12 mg/m2 (days 1-3), oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.
Consolidation: Cytarabine IV infusion 1,5-3 g/m2 (days 1, 3, 5), oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.
Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Induction: Cytarabine continuous IV infusion 200 mg/m2 (days 1-7), Idarubicin IV infusion 12 mg/m2 (days 1-3), oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.
Consolidation: Cytarabine IV infusion 1,5-3 g/m2 (days 1, 3, 5), oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.
Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quizartinib</intervention_name>
    <description>Induction: oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.
Consolidation: oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.
Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days.</description>
    <arm_group_label>Quizartinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Induction: oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.
Consolidation: oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.
Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.
Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Quizartinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Quizartinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent in accordance with national, local, and institutional
             guidelines. The patient must provide informed consent before the first screening
             procedure. The patient and the investigator must sign informed consent form.

          2. Diagnosis of untreated AML (according to the World Health Organization (WHO) 2008/2016
             definition)

          3. Age ≥ 18 and ≤70 years old at the time of screening

          4. Non-FLT3-ITD (allelic ratio &lt;0.03) at diagnosis

          5. Considered eligible to receive intensive chemotherapy as per investigator judgment

          6. Eastern Cooperative Oncology Group (ECOG) 0-2

          7. No contraindications for quizartinib

          8. The subject is receiving standard &quot;7+3&quot; induction chemotherapy regimen as specified in
             the protocol

          9. No severe organ function abnormalities

         10. Not included in other first-line trials

         11. Cardiac ejection fraction ≥ 45% assessed by echocardiography or multiple-gated
             acquisition (MUGA).

         12. Female patients of child-bearing potential must have a negative serum pregnancy test
             at screening and agree to use reliable methods of contraception upon enrollment,
             during the treatment period and for 3 months following the last dose of
             investigational drug or cytarabine, whichever is later

         13. Male patients must use a reliable method of contraception (if sexually active with a
             female of child-bearing potential) upon enrollment, during the treatment period, and
             for 3 months following the last dose of investigational drug or cytarabine, whichever
             is later

         14. Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedures.

        Exclusion Criteria:

          1. Patients with a genetic diagnosis of acute promyelocytic leukemia

          2. Age &lt;18 years or &gt;70 years

          3. ECOG performance status of 3 or 4

          4. Prior treatment for AML, except for the following allowances:

             c) Leukapheresis d) Treatment for hyperleukocytosis with hydroxyurea

          5. Blastic phase of bcr/abl chronic myeloid leukemia.

          6. Presence of an associated active and/or uncontrolled malignancy:

             - Patients with another neoplastic disease, for whom the Investigator has a clinical
             suspicion of active disease at the time of enrollment. Note: Patients with adequately
             treated early stage squamous cell carcinoma of the skin, basal cell carcinoma of the
             skin, or cervical intraepithelial neoplasia are eligible for this study. Hormonal or
             adjuvant therapies will be allowed for breast cancer or prostate cancer as long as
             they are on a stable dose for at least 2 weeks before the first dose.

          7. Known active and not controlled hepatitis B or hepatitis C infection. In the event of
             a positive viral load, please consult with the Sponsor

          8. Known human immunodeficiency virus (HIV) infection (HIV testing is not required as
             part of this study)

          9. Presence of any severe psychiatric disease or physical condition that, according to
             the physician´s criteria, contraindicates the inclusion of the patient into the
             clinical trial

         10. Serum creatinine ≥ 250 μmol/l (≥ 2.5 mg/dL) (unless it is attributable to AML
             activity)

         11. Bilirubin, alkaline phosphatase, or Serum glutamic oxaloacetic transaminase (SGOT) &gt; 3
             times the normal upper limit (unless it is attributable to AML activity)

         12. Uncontrolled or significant cardiovascular disease, including any of the following:

               1. Symptomatic bradycardia of fewer than 50 beats per minute, unless the subject has
                  a pacemaker;

               2. QT Comparison of Fridericia's (QTcF) &gt;450 msec at Screening. Note: QTcF will be
                  derived from the mean of triplicate readings;

               3. Diagnosis of or suspicion of long QT syndrome (including family history of long
                  QT syndrome);

               4. Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥ 110 mmHg;

               5. History of clinically relevant ventricular arrhythmias (e.g., ventricular
                  tachycardia, ventricular fibrillation, or Torsade de Pointes)

               6. History of a second (Mobitz II) or third-degree heart block (subjects with
                  pacemakers are eligible if they have no history of fainting or clinically
                  relevant arrhythmias while using the pacemaker)

               7. An ejection fraction &lt;45%

               8. History of uncontrolled angina pectoris or myocardial infarction within 6 months
                  prior to Screening

               9. History of New York Heart Association Class 3 or 4 heart failure

              10. Right bundle branch and left anterior hemiblock (bifascicular block), complete
                  left bundle branch block

         13. History of hypersensitivity to any excipients in the quizartinib/placebo tablets

         14. Females who are pregnant or breastfeeding

         15. Any patients with known significant impairment in gastrointestinal function or
             gastrointestinal disease that may significantly alter the absorption of quizartinib.

         16. Active acute or chronic Graft-Versus-Host-Disease (GVHD) requiring prednisone &gt;10 mg
             or equivalent corticosteroid daily.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pau Montesinos</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari i Politecnic La Fe</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fátima González Hurtado</last_name>
    <phone>+34 914561105</phone>
    <email>ensayosclinicos@dynasolutions.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carmen López-Carrero</last_name>
    <phone>+34 699835437</phone>
    <email>gerencia@fundacionpethema.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de A Coruña</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Víctor Noriega Concepción</last_name>
      <email>victor.noriega.concepcion@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Víctor Noriega Concepción</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Alonso Vence</last_name>
      <email>natalia.alonso.vence@sergas.es</email>
    </contact>
    <contact_backup>
      <last_name>Beatriz Antelo</last_name>
      <email>beatriz.antelo@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Natalia Alonso Vence</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Vives Polo</last_name>
      <email>svives@iconcologia.net</email>
    </contact>
    <contact_backup>
      <last_name>Esther Gracia</last_name>
      <email>egracia@igtp.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Susana Vives Polo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Univesitario de Castellón</name>
      <address>
        <city>Castellón De La Plana</city>
        <state>Castellón</state>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raimundo García Boyero</last_name>
      <email>garcia_rai@gva.es</email>
    </contact>
    <investigator>
      <last_name>Raimundo García Boyero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Las Palmas</state>
        <zip>35020</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Santiago Jiménez Bravo de Laguna</last_name>
      <email>jsimbra@gobiernodecanarias.org</email>
    </contact>
    <contact_backup>
      <last_name>Elena González Pérez</last_name>
      <email>gpelena88@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Santiago Jiménez Bravo de Laguna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quirón Salud Madrid</name>
      <address>
        <city>Pozuelo De Alarcón</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Martínez Chamorro</last_name>
      <email>carmenmartinezchamorro@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Carmen Martínez Chamorro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Santa Lucía</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <zip>30200</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Martínez Francés</last_name>
      <email>amartifran@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Martínez Francés</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra Suárez Ordóñez</last_name>
      <email>sandra.suarez.ordonez@sergas.es</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Fariñas</last_name>
      <email>hematologia.vigo@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sandra Suárez Ordóñez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernardo Javier González</last_name>
      <email>bjgonzalez@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Bernardo Javier González</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Arce Fernández</last_name>
      <email>olga.arcefernandez@osakidetza.eus</email>
    </contact>
    <investigator>
      <last_name>Olga Arce Fernández</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Galdakao</name>
      <address>
        <city>Galdakao</city>
        <state>Vizcaya</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matxalen Olivares Salaverri</last_name>
      <email>MATXALEN.OLIVARESSALAVERRI@osakidetza.eus</email>
    </contact>
    <investigator>
      <last_name>Matxalen Olivares Salaverri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesús Lorenzo Algarra Algarra</last_name>
      <email>jlalgarra@sescam.jccm.es</email>
    </contact>
    <investigator>
      <last_name>Jesús Lorenzo Algarra Algarra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Botella Prieto</last_name>
      <email>carmenbotellap@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Carmen Botella Prieto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Torrecárdenas</name>
      <address>
        <city>Almería</city>
        <zip>04004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María José García Pérez</last_name>
      <email>mj.garciaper@gmail.com</email>
    </contact>
    <investigator>
      <last_name>María José García Pérez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olga Salamero García</last_name>
      <email>osalamero@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Olga Salamero García</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge Labrador Gómez</last_name>
      <email>jlabradorg@saludcastillayleon.es</email>
    </contact>
    <investigator>
      <last_name>Jorge Labrador Gómez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Miguel Bergua Burgues</last_name>
      <email>jmberguaburg@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mamen Alcaine</last_name>
      <email>mamenalca@achh.es</email>
    </contact_backup>
    <investigator>
      <last_name>Juan Miguel Bergua Burgues</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josefina Serrano López</last_name>
      <email>josefina.serrano@iname.com</email>
    </contact>
    <contact_backup>
      <last_name>Juan Miguel Serra</last_name>
      <email>datamanager1hurs@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Josefina Serrano López</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Romero Aguilar</last_name>
      <email>antonio.romero.aguilar.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Antonio Romero Aguilar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Ramón Jiménez</name>
      <address>
        <city>Huelva</city>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Solé Rodríguez</last_name>
      <email>masrodriguez5983@gmail.com</email>
    </contact>
    <investigator>
      <last_name>María Solé Rodríguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Antonio López López</last_name>
      <email>juan.antonio.lopez.hematologia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Antonio López López</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María José Sánchez Sánchez</last_name>
      <email>maria.jose.sanchez.sanchez3@sergas.es</email>
    </contact>
    <investigator>
      <last_name>María José Sánchez Sánchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Luis López Lorenzo</last_name>
      <email>jllopez@fjd.es</email>
    </contact>
    <investigator>
      <last_name>José Luis López Lorenzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María Calbacho Robles</last_name>
      <email>mcalbachorobles@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Pilar Portasany</last_name>
      <email>pilar.portasany@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>María Calbacho Robles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel Barrios García</last_name>
      <email>manbagarmed@yahoo.es</email>
    </contact>
    <contact_backup>
      <last_name>Beatriz Gago</last_name>
      <email>beagc91@hotmail.es</email>
    </contact_backup>
    <investigator>
      <last_name>Manuel Barrios García</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfonso Fernández Fernández</last_name>
      <email>alfonsoff@outlook.es</email>
    </contact>
    <investigator>
      <last_name>Alfonso Fernández Fernández</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Bernal del Castillo</last_name>
      <email>bernaldelcastillo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Teresa Bernal del Castillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Universitario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mª Carmen Mateos Rodríguez</last_name>
      <email>mmateosr@navarra.es</email>
    </contact>
    <investigator>
      <last_name>Mª Carmen Mateos Rodríguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María Lourdes Amador Barciela</last_name>
      <email>maria.lourdes.amador.barciela@sergas.es</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Fariñas</last_name>
      <email>hematologia.pontevedra@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>María Lourdes Amador Barciela</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María Belén Vidriales</last_name>
      <email>mbvidriales@saludcastillayleon.es</email>
    </contact>
    <investigator>
      <last_name>María Belén Vidriales</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Colorado Araujo</last_name>
      <email>mcoloradoa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Pilar González Echezarreta</last_name>
      <email>mpilar.gonzaleze@scsalud.es</email>
    </contact_backup>
    <investigator>
      <last_name>Mercedes Colorado Araujo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Antonio Pérez Simón</last_name>
      <email>josea.perez.simon.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>José Antonio Pérez Simón</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Toledo</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María Isabel Gómez Roncero</last_name>
      <email>mgroncero@sescam.jccm.es</email>
    </contact>
    <contact_backup>
      <last_name>Nuria García</last_name>
      <email>ceganur@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>María Isabel Gómez Roncero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María del Mar Tormo Díaz</last_name>
      <email>tormo_mar@gva.es</email>
    </contact>
    <investigator>
      <last_name>María del Mar Tormo Díaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset Aleixandre</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria José Sayas Lloris</last_name>
      <email>sayas_mjo@gva.es</email>
    </contact>
    <investigator>
      <last_name>Maria José Sayas Lloris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebeca Rodríguez Veiga</last_name>
      <email>rodriguez_reb@gva.es</email>
    </contact>
    <contact_backup>
      <last_name>Pau Montesinos</last_name>
      <email>montesinos_pau@gva.es</email>
    </contact_backup>
    <investigator>
      <last_name>Rebeca Rodríguez Veiga</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pau Montesinos</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Cano</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Martínez-Cuadrón</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Blanca Boluda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebeca Cuello García</last_name>
      <email>rcuellogarcia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rebeca Cuello García</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María Teresa Olave Rubio</last_name>
      <email>tolave@salud.aragon.es</email>
    </contact>
    <investigator>
      <last_name>María Teresa Olave Rubio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lissette Costilla Barriga</last_name>
      <email>ldpcostilla@salud.aragon.es</email>
    </contact>
    <investigator>
      <last_name>Lissette Costilla Barriga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Txagorritxu</name>
      <address>
        <city>Vitoria</city>
        <state>Álava</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laida Cuevas Palomares</last_name>
      <email>LAIDA.CUEVASPALOMARES@osakidetza.eus</email>
    </contact>
    <investigator>
      <last_name>Laida Cuevas Palomares</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quizartinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

